Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/Ib study of INT-1B3 in advanced solid tumors
NL-OMON52968Phase 1Not yet recruiting
- Sponsor
- InteRNA Technologies
- Start
- Feb 2021
- Modality
- Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of INT-1B3 in Nonhematologic neoplasms, hepatocellular carcinoma (HCC) and triple-negative breast cancer (TNBC) (2 arms), sponsored by InteRNA Technologies. Primary endpoints: Safety and tolerability and Recommended phase 2 dose. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
INT-1B3
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON52968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52968.